News | October 29, 2021
Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
The NFI is published to promote the rational use of medicines in the country.
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Acute therapies continue to report strong growth compared to chronic ones.
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
_1_256_384.png)
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Cipla has reported consolidated financial results for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Subscribe To Our Newsletter & Stay Updated
